Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
83.95 EUR | +1.51% | +3.54% | +38.37% |
02/04 | Spain's Rovi Obtains US FDA Approval for Marketing Risvan as Schizophrenia Treatment | MT |
12/03 | Rovi, Partners to Form Entity for Advanced Therapies R&D | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+38.37% | 4.59B | |
+26.47% | 664B | |
+25.70% | 567B | |
-6.33% | 354B | |
+19.35% | 330B | |
+4.23% | 286B | |
+13.42% | 234B | |
+4.71% | 199B | |
-10.10% | 196B | |
-4.04% | 148B |
- Stock Market
- Equities
- ROVI Stock
- News Laboratorios Farmaceuticos Rovi, S.A.
- Moderna struggles with vaccine ramp-up, cuts 2021 sales view; shares drop